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Figure 2. Highest Toxicity Level Across All Body Symptoms (fever in the
absence of signs of infection. fatigue, skin rash, local reactions, nausea, vom-
iting, anorexia, insomnia, dizziness, and syncope) experienced by PBSC donors,
by unrelated vs. related donors, at baseline, donation, and 1 year post-
donation.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S42donation-related grade 2-4 pain, grade 3-4 pain, and grade 2-
4 MTC (Table 2) compared to URDs of PBSC. In addition, RDs
of PBSC were less likely than URDs of PBSC to return to
baseline levels of pain and MTC at 1 year. Although only a
small fraction of both URDs and RDs reported grade 2-4
pain/MTC 1 year post-donation (Table 1), RDs were 2-3
times more likely to report pain/MTC at 1 year than URDs.
Conclusions: RDs of PBSC have more baseline and donation-
related pain/MTC and less complete 1 year recovery than
URDs. Ongoing analysis of baseline health status of RDs on
the RDSafe trial is underway to further deﬁne differences
between RDs/URDs that could account for these higher levels
of pain/MTC.Fig. 1. CD8 cell dose and overall survival.21
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Peripheral blood stem cells (PBSC) are the major source for
allogeneic stem cell transplantations. It has been shown that
treatment with 7.5 mg/kg G-CSF for 5 days is sufﬁcient to
mobilize and collect required CD34+ cells for transplantation.
However, uncertainty remains in 0.5e5.0% of all donors
regarding insufﬁcient mobilization. In this retrospective
analysis we evaluated 5691 allogeneic stem cell mobilization
regimens (72% male vs. 28% female donors) from two major
collection centers focusing on donor risk factors for poor
mobilization. According to our historical reciprocal weight
and BMI-adapted mobilization protocol low weight/low BMI
donors received > 8.3mg/kg/d for 4 days, whereas overweight
donors received <7.5 mg/kg. At day 5 all donors received
526mg G-CSF 2 hours before apheresis. In total, a mean G-CSF-
dosis of 8.9  1.0mg/kg/d for 5 days has been utilized (min
4.5mg/kg/d e max. 15.9mg/kg/d). Mean CD34+ cell concentra-
tion of 95 49/ml could be achieved in the peripheral blood at
day 5 before starting apheresis. This enabled us to collect amean of 9.7  8.0 CD34+ cells/kg body weight recipient cor-
responding to 658  252 million total CD34+ cells in the
product. In 96.3% of all cases one single apheresis was sufﬁ-
cient to collect the requested amount of CD34+ cells. Using
logistic regression analysis we deﬁned female sex, low BMI
and low platelet (PLT) count at baseline as strongest risk fac-
tors for poor mobilization. Low white blood cell (WBC) con-
centration, low hematocrit and G-CSF-doses < 9mg/kg/d were
also signiﬁcantly associated with poor mobilization. Using the
strongest numeric predictors (BMI, PLT) we employed STEPP-
analysis to establish a statistically signiﬁcant cross table risk
score, that allows prediction of CD34+ cells in the peripheral
blood at day 5 according to baseline PLT and BMI. From lowest
cumulative risk score 2 (PLT>290; BMI>34.5) to highest risk
score 6 (PLT<170; BMI<20.7) differences between all risk
scoreswere highly signiﬁcant. Interestingly, subgroup analysis
demonstrated that female but not male donors with poor risk
score that received > 9mg/kg/d G-CSF could improve signiﬁ-
cantly mobilization outcome without further side effects.
Thus, overall results demonstrated that weight adapted G-CSF
dosage for allogeneic donor treatment may improve mobili-
zation outcome, i.e. in poor risk prospect female donors with
low BMI and low PLT at baseline. Further genetic analysis may
identify factors responsible for mobilization outcome.22
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Background: Younger donor age is associated with better
survival in unrelated donor bone marrow transplants, but
young unrelated donors have not shown an overall survival
Fig. 2. Donor age and CD8 cell dose.
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ported that a high CD8 T-cell content of peripheral blood (PB)
stem-cell grafts was associated with improved OS in reduced
intensity alloSCT (Reshef et al, Tandem, 2014). In this study
we examined whether donor age correlated with graft T-cell
content, and whether CD8 T-cell content may inform the
selection of an optimal donor.
Methods: We studied 200 patients (pts) who underwent PB
alloSCT after Flu/Bu2 conditioning (2007 to 2014). Cumula-
tive incidence and Cox regression analyses were used to
evaluate associations between cell doses and outcomes, with
adjustment for signiﬁcant covariates.
Results
Patients
The median age was 62 (range 21-76) and diseases
included AML (86), MDS (44), NHL (30), ALL (11), CLL (8) and
others (21). Pts were allografted from HLA-matched (86%) or
mismatched (14%); sibling (42.5%) or unrelated (57.5%)
donors.Outcomes
A higher CD8 cell dose was associated with a decreased
risk of relapse and improved OS. The adjusted hazard ratios
(aHR) per 1 x 108/kg CD8 cells were: relapse 0.43 (95% CI
[0.23 e 0.81]), p ¼ 0.009; OS 0.57 (95% CI [0.33 e 0.97]), p ¼
0.04. A cutoff of 0.72 x 108/kg CD8 cells optimally dichoto-
mized pts with differing OS. Pts who received a CD8hi
(>¼0.72) graft had signiﬁcantly improved OS (aHR ¼ 0.53, p
¼ 0.007; Fig 1). The 1-year survival rates were 77.1% forFig. 3. Survival of recipients (age>60) is better with young unrelated donors
and a CD8hi graft.CD8hi grafts and 50.2% for CD8lo grafts (p ¼ 0.0002). CD3,
CD4 and CD8 doses were not associated with GvHD or NRM.
Donors
Donor age inversely correlated with CD8 cell doses (r ¼
-0.44, p < 0.0001; Fig 2). All donors over age 60 provided a
CD8lo graft while 45% of donors under age 40 provided a
CD8hi graft. In recipients over age 60 (n¼118; Fig 3), OS was
better for patients allografted from young unrelated donors
with a CD8hi graft compared to older sibling donors (p ¼
0.002) or young unrelated donors with a CD8lo graft (p ¼
0.002). The OS beneﬁt was driven by a reduction in relapse
risk without signiﬁcant differences in GVHD or NRM. We
then investigated whether a high CD8 cell dose could be
predicted during donor screening. We found that donors
(n¼23) whose grafts contained a higher CD8 cell dose had
higher %CD8 cells (r ¼ 0.69, p ¼ 0.0004) and lower CD4/8
ratio (r ¼ -0.55, p ¼ 0.007) in a screening blood sample.
Conclusion: A higher CD8 cell dose is associated with
improved survival after reduced intensity alloSCT. Young
unrelated donors with CD8hi grafts lead to better survival
compared to older sibling donors. Donor selection based on
predicted CD8 cell dose should be considered in prospective
trials of reduced intensity alloSCT.
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Introduction: Delayed neutrophil recovery after myelo-
ablative DCBT (median 25 days in adults) is frequent &
associated with prolonged hospitalization & increased
transplant-related mortality.
Methods:We investigated DCBTcombined with haploCD34+
cells to speed myeloid recovery.
Results: Between 9/2012-8/201416/55 (29%) eligible patients
(pts) could not receive DCBT-haplo as they had no haplo (n ¼
10) or had no CB  no haplo graft (n ¼ 6). 39 pts (median 48
years, range 15-68) with high-risk hematologic malignancies
[30 acute leukemias (25 morphologic CR or aplasia, 5 not in
CR) & 9 advanced lymphomas] underwent DCBT-haploCD34+
after myeloablation (2 high-dose Cy/Flu/TBI-1375, 37 reduced
intensity Cy/Flu/Thio/TBI-400) with CSA/MMF & no ATG. CB
units had a median infused TNC x 107/kg of 2.30 (larger unit)
& 1.86 (smaller unit), & a median donor-recipient HLA-allele
match of 5/8 (range 2-7/8). Haplo-donors (median 37 years,
range 15-71) had a median 4/8 (range 4-6/8) donor-recipient
HLA-match. The median infused haploCD34+ cell dose was
